Quick answer

Factor V Leiden mutation (present in ~5% of Caucasians) renders factor V resistant to protein-C inactivation — tripling DVT risk in heterozygotes, 10-20× in homozygotes. Testing belongs after unexplained clots, in young thrombosis, or with strong family clotting history.

The genetic mechanism

Activated protein C normally clips factor V, braking coagulation. Leiden mutation (Arg506Gln) blocks this cleavage site — the brake fails, clotting continues unchecked. Prevalence: ~5% European ancestry, lower in other populations. Homozygous (~1-in-5000) carries substantially higher risk than heterozygous.

Who deserves testing

  • First DVT/PE before age 50
  • Recurrent thrombosis
  • Unusual-site thrombosis (cerebral/splanchnic/mesenteric)
  • Strong family history of venous thromboembolism
  • Warfarin-induced skin necrosis (protein-C deficiency overlap)
  • Women with pregnancy loss + thrombosis history

Testing healthy relatives of known carriers remains debated — disclosure anxiety trades against prevention knowledge.

What testing positive means practically

Heterozygotes: first unprovoked DVT → indefinite anticoagulation typically; provoked DVT → standard 3-month course. Homozygotes: more aggressive prevention thresholds. All carriers: minimize additional risk factors (smoking, estrogen-containing contraceptives/HRT, prolonged immobility).

Management nuance

Estrogen-containing contraception TRIPLES DVT risk in heterozygotes (from 3× baseline to 9×) — alternative contraception strongly recommended in identified carriers. Surgery/hospitalization thromboprophylaxis standard. Pregnancy: antepartum/postpartum prophylaxis decisions by thrombosis history.

Order this test online

Direct-access laboratory testing — no appointment or doctor visit required. Results delivered as secure PDFs.

We may earn a commission when you order through partner links. Educational content only — never a substitute for professional medical advice.

Related guides

Frequently asked questions

Should I test before starting birth control?

Selective screening (family history of clots) recommended; universal screening not — too many needed-to-test for one prevented event.

Does FVL cause heart attacks or strokes?

Arterial thrombosis (MI/stroke) shows weak/absent association — FVL is a VENOUS-clotting risk factor specifically.